Mark is Chief Scientist in Oncology at AstraZeneca (AZ), based in Cambridge, United Kingdom, where he heads up the DNA Damage Response (DDR) strategic biology area. He earned a Ph.D. in biochemistry from Bristol University and carried out his postdoctoral research at the Institute of Molecular and Cell Biology in Singapore, working on the biology of human papillomavirus and the link to cervical cancer
In 1999, Mark returned to the UK to become research team leader at the Cambridge start-up and DDR specialist biotech company KuDOS, and was promoted to Chief Scientist there in 2009. Since 2006, when AstraZeneca acquired KuDOS, Mark has provided scientific leadership on olaparib (Lynparza), the first-in-class oral poly (ADP-ribose) polymerase (PARP) inhibitor, through its transfer to AZ and approval in the United States and Europe in 2014. Mark also championed the in-licensing of the WEE1 inhibitor (AZD1775) in 2013 and has played a key role in the growth of DDR within AZ to an industry-leading portfolio comprising seven DDR projects with six inhibitors currently in clinical development. As well as being a named inventor on multiple patents, Mark has publications that include papers in Cell, Molecular Cell, Nature Cell Biology and New England Journal of Medicine.